Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -37.16% is 13% below its 1-year average of -32.95%, near the low end of its 1-year range (-37.16%–-28.75%).
As of the fiscal period ended Wednesday, December 31, 2025. 12.76% below its 12-month average of -32.95%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -19.14%.
RETURN ON ASSETS (ROA)
-37.16%
RETURN ON ASSETS (ROA) AVG TTM
-32.95%
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-12.76%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.23%
median of 384 covered companies
CURRENT VS SECTOR MEDIAN
-60.00%
vs the sector median at left
BlossomHill Therapeutics, Inc.
Market Cap
$579.88M
Return on Assets (ROA)
-37.16%
TTM Avg
-32.95%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$573.38M
Return on Assets (ROA)
-59.22%
TTM Avg
-47.88%
3Y Avg
-51.20%
5Y Avg
-67.88%
Market Cap
$569.56M
Return on Assets (ROA)
20.70%
TTM Avg
2.32%
3Y Avg
-24.93%
5Y Avg
-30.88%
Market Cap
$596.36M
Return on Assets (ROA)
-42.15%
TTM Avg
-50.20%
3Y Avg
-44.84%
5Y Avg
-47.93%
Market Cap
$561.67M
Return on Assets (ROA)
-20.89%
TTM Avg
7.49%
3Y Avg
-5.84%
5Y Avg
-12.60%
Market Cap
$547.86M
Return on Assets (ROA)
0.39%
TTM Avg
-16.14%
3Y Avg
-90.03%
5Y Avg
-84.55%
Market Cap
$632.76M
Return on Assets (ROA)
-23.40%
TTM Avg
-34.85%
3Y Avg
-33.75%
5Y Avg
-41.05%
Market Cap
$637.59M
Return on Assets (ROA)
-7.75%
TTM Avg
-4.25%
3Y Avg
-2.93%
5Y Avg
9.76%
Market Cap
$519.25M
Return on Assets (ROA)
-17.40%
TTM Avg
-49.85%
3Y Avg
-45.66%
5Y Avg
-41.17%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) | $579.88M | -37.16% | -32.95% | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | -59.22% | -47.88% | -51.20% | -67.88% |
| CorMedix Inc. (CRMD)vs › | $569.56M | 20.70% | 2.32% | -24.93% | -30.88% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | -42.15% | -50.20% | -44.84% | -47.93% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | -20.89% | 7.49% | -5.84% | -12.60% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 0.39% | -16.14% | -90.03% | -84.55% |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | -23.40% | -34.85% | -33.75% | -41.05% |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | -7.75% | -4.25% | -2.93% | 9.76% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -17.40% | -49.85% | -45.66% | -41.17% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -89.18% | -100.15% | -92.96% | -79.13% |
ROA
-37.2%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -37.16% |
| 2024-12-31 | -28.75% |
